HSV Testing Market Size & Growth Forecast 2027–2036, By Segments (Type, Sample Type, Test Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Type Segment Analysis: HSV-1/HSV-2 Combines (Largest Segment) vs HSV-2 (Fastest-Growing Segment)

HSV-1/HSV-2 combined tests accounted for the largest share of the type segment in 2026, with a 51.89% revenue share, reflecting the clinical value of testing approaches capable of identifying infections associated with both herpes simplex virus types. Combined testing can support broader diagnostic assessment when the specific viral type is uncertain, enabling healthcare professionals to obtain more comprehensive information from a single testing approach. The availability of differentiated diagnostic information is particularly important because HSV-1 and HSV-2 can differ in their typical patterns of infection and transmission. Growing awareness of sexually transmitted infections, increasing emphasis on accurate diagnosis, and the need for appropriate patient management are supporting demand for comprehensive HSV testing. Improvements in laboratory diagnostics and greater accessibility of testing services are also contributing to the continued importance of combined testing approaches.

HSV-2 is projected to be the fastest-growing type segment, driven by increasing attention to genital herpes diagnosis and the need for more targeted identification of HSV-2 infections. Greater awareness of sexually transmitted infections is encouraging individuals and healthcare providers to pursue testing when symptoms or exposure risks are present. More specific diagnostic information can support appropriate counseling, management, and prevention strategies, particularly where distinguishing HSV-2 from other herpes simplex infections is clinically relevant. Improvements in test sensitivity, accessibility, and turnaround times are further supporting adoption of HSV-2-specific testing. The expansion of screening and diagnostic services is expected to strengthen demand for targeted HSV-2 testing across healthcare settings.

Sample Type Segment Analysis: Blood (Largest & Fastest-Growing Segment)

Blood testing represents both the largest and fastest-growing sample type segment in the HSV testing market in 2026, supported by its established role in serological assessment and its ability to provide diagnostic information through a relatively accessible specimen. Blood samples can be used to detect antibodies associated with HSV infection, making them useful when determining previous exposure or supporting diagnosis in situations where direct sampling of lesions is not practical. The familiarity of blood collection procedures across healthcare settings also contributes to the segment's broad adoption. Increasing awareness of HSV infections, greater demand for accessible diagnostic services, and continued use of laboratory-based serological methods are supporting growth. As testing becomes more widely incorporated into clinical evaluation and screening pathways, the convenience and established infrastructure surrounding blood-based testing are expected to reinforce its position across the sample type segment.

Test Type Segment Analysis: Serological Tests (Largest Segment) vs Point-of-care Tests (Fastest-Growing Segment)

Serological tests held the largest share of the test type segment in 2026, reflecting their established use in identifying antibodies associated with HSV infection and supporting diagnostic assessment when direct detection of the virus may not be suitable. These tests can provide valuable information regarding prior exposure and are particularly relevant in cases where patients may not have active lesions at the time of evaluation. Their integration into established laboratory workflows, combined with the availability of standardized testing procedures, supports continued utilization across healthcare settings. Growing awareness of HSV diagnosis and the need for reliable laboratory-based assessment are contributing to sustained demand for serological testing. Continued improvements in diagnostic accuracy and testing accessibility are also supporting the segment's established position.

Point-of-care tests are projected to be the fastest-growing test type segment, driven by demand for faster diagnostic assessment and greater accessibility outside traditional laboratory environments. Point-of-care testing can reduce delays associated with sample transportation and laboratory processing, making it attractive for healthcare settings where timely clinical decisions are important. Increasing emphasis on convenient testing, decentralized healthcare delivery, and improved patient access is encouraging the development and adoption of rapid diagnostic approaches. Advances in test performance and user-friendly testing formats are further expanding their potential application. As healthcare providers seek more efficient diagnostic pathways and patients increasingly value rapid access to testing, point-of-care HSV testing is expected to gain greater adoption across diverse care settings.